the aid library

LIST OPTIONS

Filter

507

Sort by:

Direction:

Download (11442)

View PDF (2290)

Sterilization Manual for Health Centers

Silvia I. Acosta-Gnass and Valeska de Andrade Stempliuk PAHO; USAID (2009) C_WHO

Download (7971)

View PDF (5650)

Practical Guidelines for Infection Control in Health Care Facilities
recommended

Manju Vatsa, Duangvadee Sungkhobol, Sudarshan Kumari, et al. WHO Western Pacific, Manila, and WHO South-East Asia, New Delhi (2004)

Download (665)

View PDF (956)

Injection providers' guide for safe injections

World Health Organization WHO (2017) C_WHO

Download (1200)

View PDF (2111)

Guidelines for Workplace TB Control Activities

Benjamin O Alli [et al.] World Health Organisation, International Labour Organization (2003) C_WHO

This World Health Organization (WHO) and the International Labour Organization (ILO) joint guidelines production aims at harnessing the contribution of employers and workers towards the control of TB. It covers all the practical steps involved in establishing TB control activities, including (for la... more

Download (788)

View PDF (1692)

Manual for the Development and Assessment of National Viral Hepatitis Plans

Joe Schofield, Sarah Hess, Bandana Malhotra et al. World Health Organization (WHO) (2015)

A Provisional Document. The purpose of this manual is to provide guidance to public health professionals tasked with managing a response to viral hepatitis. As every country’s needs are different with respect to its epidemiology and the current level of response, people would use this manual in di... more

Download (669)

View PDF (1505)

Safe management of wastes from health-care activities: A summary

World Health Organization (WHO) (2017) CC

This document highlights the key aspects of safe health-care waste management in order to guide policy-makers, practitioners and facility managers to improve such services in health-care facilities. It is based on the comprehensive WHO handbook Safe management of wastes from health-care activities (... more

Download (334)

View PDF (1920)

Disease Control Priorities, Third Edition : Volume 1. Essential Surgery

Debas, Haile T.; Donkor, Peter; Gawande, Atul; et al. (2015) CC

The volume presents data on the surgical burden of disease, disability, congenital anomalies, and trauma, along with health impact and economic analyses of procedures, platforms, and packages to improve care in settings with severe budget limitations. Essential Surgery identifies 44 surgical procedu... more

Download (842)

View PDF (1869)

Report of a meeting of the WHO Expert Committee on the Control of Leishmaniases, Geneva, 22–26 March 2010

WHO (2010)

Download (1287)

View PDF (3012)

Tool for the assessment of injection safety

World Health Organization (2001) C_WHO

Download (725)

View PDF (1439)

Preventing violence and reducing its impact: how development agencies can help.

Alexander Butchart, David Brown, Andrew Wilson, and Christopher Mikton World Health Organization (2008)

Download (1425)

View PDF (2577)

WHO guideline on the use of safety-engineered syringes for intramuscular, intradermal and subcutaneous injections in health-care settings
recommended

World Health Organization (2016) C_WHO

Download (942)

View PDF (1922)

Tool to assess the association between injections and infections

World Health Organization (2001)

Download (813)

View PDF (1606)

Policy on TB Control in Health Care Facilities, Congregate Settings and Households

World Health Organization WHO (2009)

This document is an evidence-based policy for the implementation of sound tuberculosis (TB) infection control by all stake- holders. It recommends a combination of measures aimed at reducing the risk of TB transmission within populations. The emphasis is on early and rapid diagnosis, and proper mana... more

Download (245)

View PDF (329)

Therapeutics and COVID-19 (Living Guideline, 10 November 2023)

World Health Organization WHO (2023) C_WHO

WHO has updated its guidelines for COVID-19 therapeutics, with revised recommendations for patients with non-severe COVID-19. This is the 13th update to these guidelines. Updated risk rates for hospital admission in patients with non-severe COVID-19 The guidance includes updated risk rates for... hospital admission in patients with non-severe COVID-19. The current COVID-19 virus variants tend to cause less severe disease while immunity levels are higher due to vaccination, leading to lower risks of severe illness and death for most patients. This update includes new baseline risk estimates for hospital admission in patients with non-severe COVID-19. The new ‘moderate risk’ category now includes people previously considered to be high risk including older people and/or those with chronic conditions, disabilities, and comorbidities of chronic disease. The updated risk estimates will assist healthcare professionals to identify individuals at high, moderate or low risk of hospital admission, and to tailor treatment according to WHO guidelines: **High: **People who are immunosuppressed remain at higher risk if they contract COVID-19, with an estimated hospitalization rate of 6%. **Moderate: **People over 65 years old, those with conditions like obesity, diabetes and/or chronic conditions including chronic obstructive pulmonary disease, kidney or liver disease, cancer, people with disabilities and those with comorbidities of chronic disease are at moderate risk, with an estimated hospitalization rate of 3%. Low: Those who are not in the high or moderate risk categories are at low risk of hospitalization (0.5%). Most people are low risk. Review of COVID-19 treatments for people with non-severe COVID-19 WHO continues to strongly recommend nirmatrelvir-ritonavir (also known by its brand name ‘Paxlovid’) for people at high-risk and moderate risk of hospitalization. The recommendations state that nirmatrelvir-ritonavir is considered the best choice for most eligible patients, given its therapeutic benefits, ease of administration and fewer concerns about potential harms. Nirmatrelvir-ritonavir was first recommended by WHO in April 2022. If nirmatrelvir-ritonavir is not available to patients at high-risk of hospitalization, WHO suggests the use of molnupiravir or remdesivir instead. WHO suggests against the use of molnupiravir and remdesivir for patients at moderate risk, judging the potential harms to outweigh the limited benefits in patients at moderate risk of hospital admission. For people at low risk of hospitalization, WHO does not recommend any antiviral therapy. Symptoms like fever and pain can continue to be managed with analgesics like paracetamol. WHO also recommends against use of a new antiviral (VV116) for patients, except in clinical trials. The update also includes a strong recommendation against the use of ivermectin for patients with non-severe COVID-19. WHO continues to advise that in patients with severe or critical COVID-19, ivermectin should only be used in clinical trials. more